The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1640
In Brief: Booster Doses of mRNA-Based COVID-19 Vaccines for All Adults
Download PDF:    US English
 Select a term to see related articles  Comirnaty   COVID-19   Spikevax   vaccines   Vaxzevria 
Original online publication date: November 22, 2021
Updated: December 9, 2021

On November 19, the FDA expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a booster dose for all adults ≥18 years old after primary immunization with either the same COVID-19 vaccine or a different one.1 Booster doses of these vaccines were previously authorized only for select populations (age ≥65 years or persons at high risk for severe COVID-19). The EUA for the adenovirus-based vaccine manufactured by Johnson & Johnson was amended in October 2021 to include administration of a booster dose for all adults ≥18 years old after primary immunization with the Johnson & Johnson vaccine.2,3

Note: On December 9, the FDA expanded the EUA of the Pfizer/BioNTech COVID-19 to include a booster dose for adolescents 16-17 years old; the CDC endorsed use of booster doses in this age group. A full review of such use will be published in a future issue.

The CDC recommends a COVID-19 booster dose for all adults ≥18 years old.4 A single booster dose of either mRNA-based COVID-19 vaccine can now be administered ≥6 months after a primary series of an mRNA-based vaccine or ≥2 months after a single primary dose of the Johnson & Johnson vaccine in all adults ≥18 years old.5,6 A single booster dose of the adenovirus-based COVID-19 vaccine can be administered to any adult ≥2 months after a single primary dose of the Johnson & Johnson vaccine or ≥6 months after a primary series of an mRNA-based vaccine (see Table 1).7

Additional Content Available:
COVID-19 Vaccine Dosing Recommendations and Comparison Chart
COVID-19 Vaccine Comparison Chart

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.